Morgan Stanley raised the firm’s price target on Abbott (ABT) to $127 from $117 and keeps an Equal Weight rating on the shares. Abbott “sounded comfortable despite macro uncertainties,” says the analyst, who sees “a lot to like” about Abbott’s defensiveness and optionality. However, this is probably captured already by the stock’s year-to-date outperformance and the stock’s premium multiple, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target raised to $140 from $134 at Oppenheimer
- Abbott Laboratories: Strong Performance and Resilience Justify Buy Rating Amid Economic Challenges
- Abbott price target raised to $142 from $132 at Raymond James
- Abbott price target raised to $145 from $140 at BTIG
- Abbott price target raised to $145 from $133 at Piper Sandler
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue